---
title: "Scinai Immunotherapeutics Secures $15 Million Equity Purchase Agreement"
description: "Scinai Immunotherapeutics Ltd. has entered a $15 million Standby Equity Purchase Agreement with YA II PN, LTD., allowing the sale of American Depositary Shares over the next 36 months. This agreement "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256925225.md"
published_at: "2025-09-11T12:14:15.000Z"
---

# Scinai Immunotherapeutics Secures $15 Million Equity Purchase Agreement

> Scinai Immunotherapeutics Ltd. has entered a $15 million Standby Equity Purchase Agreement with YA II PN, LTD., allowing the sale of American Depositary Shares over the next 36 months. This agreement aims to enhance financial flexibility and investor confidence. However, Scinai faces challenges like negative cash flows and high debt, leading to a neutral rating from Spark, TipRanks’ AI Analyst. The company operates in the biotechnology sector and trades on Nasdaq under the symbol 'SCNI'.

The latest update is out from Scinai Immunotherapeutics ( (SCNI) ).

On September 10, 2025, Scinai Immunotherapeutics Ltd. entered into a Standby Equity Purchase Agreement with YA II PN, LTD., allowing the company to sell up to $15 million of its American Depositary Shares over the next 36 months. This agreement provides Scinai with financial flexibility to raise capital as needed, potentially impacting its market position by enhancing its operational capabilities and investor confidence. The agreement includes conditions such as a registration statement with the SEC and limits on Yorkville’s ownership to prevent exceeding 9.99% of the company’s voting power.

**Spark’s Take on SCNI Stock**

According to Spark, TipRanks’ AI Analyst, SCNI is a Neutral.

Scinai Immunotherapeutics is undergoing a financial recovery but faces significant challenges such as negative cash flows and high debt levels. The stock shows neutral technical indicators, suggesting moderate market confidence. Its attractive valuation might appeal to value investors, but the absence of dividends and financial risks may deter more conservative investors.

To see Spark’s full report on SCNI stock, click here.

**More about Scinai Immunotherapeutics**

Scinai Immunotherapeutics Ltd. operates in the biotechnology industry, focusing on the development and commercialization of therapeutic products. The company is based in Jerusalem, Israel, and its primary market focus includes the sale of American Depositary Shares (ADSs) on the Nasdaq Stock Market under the symbol ‘SCNI’.

**Average Trading Volume:** 1,111,139

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $1.31M

For a thorough assessment of SCNI stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [SCNI.US - Scinai Immunotherapeutics](https://longbridge.com/en/quote/SCNI.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Decidr AI Industries Says Sugarwork Partnered With US PE Advisory Beckway Group | Decidr AI Industries Ltd :SUGARWORK PARTNERS WITH US PE ADVISORY BECKWAY GROUP | [Link](https://longbridge.com/en/news/275835609.md) |
| 08:22 ETSecureClaw by Adversa AI Launches as the First OWASP-Aligned Open-Source Security Plugin and Skill for OpenClaw AI Agents | Adversa AI has launched SecureClaw, the first open-source security plugin and skill aligned with OWASP for OpenClaw AI a | [Link](https://longbridge.com/en/news/276059372.md) |
| Should You Bet on a Short Squeeze in SoundHound AI Stock Now? | Should You Bet on a Short Squeeze in SoundHound AI Stock Now? | [Link](https://longbridge.com/en/news/275918992.md) |
| Shield AI Looking to Raise Up to $1 Billion in New Funding Round | Shield AI Looking to Raise Up to $1 Billion in New Funding Round | [Link](https://longbridge.com/en/news/275921852.md) |
| AI CEO warns AI's disruption will be 'much bigger' than COVID: 'The people I care about deserve to hear what is coming' | AI CEO warns AI's disruption will be 'much bigger' than COVID: 'The people I care about deserve to hear what is coming' | [Link](https://longbridge.com/en/news/275641811.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.